

[1］Werle-Lapostolle B，Bowden S，Locarnini S，et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy ［J］.Gastroenterology，2004，126(7)：1750-1758. 

[2］Busca A，Kumar A.Innate immune responses in hepatitis B virus (HBV) infection ［J］.Virol J，2014，11：22. 

[3］Glebe D.Recent advances in hepatitis B virus research：a German point of view ［J］.World J Gastroenterol，2007，13(1)：8-13. 

[4］Chan C，Abu-Raddad E，Golor G，et al.Clinical phamacokinetics of alamifovir and its metabolites ［J］.Antimicrob Agents Chemother，2005，49(5)：1813-1822. 

[5］Bertoletti A，Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections：towards restoration of immune control of viral infection ［J］.Gut，2012，61(12)：1754-1764. 

[6］Marcellin P，Asselah T.Long-term therapy for chronic hepatitis B：hepatitis B virus DNA suppression leading to cirrhosis reversal ［J］.J Gastroenterol Hepatol，2013，28(6)：912-923. 

[7］Chinese Society of Hepatology and Chinese Society of Infectious Diseases，Chinese Medical Association.The guidelines of prevention and treatment for chronic hepatitis B (2010 version) ［J］.Zhongguo Bingdubing Zazhi，2011，1(1)：9-23(in Chinese).中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) ［J］.中国病毒病杂志，2011，1(1)：9-23. 

[8］European Association for the Study of the Liver.EASL clinical practice guidelines：management of chronic hepatitis B virus infection ［J］.J Hepatol，2012，57(1)：167-185. 

[9］Liaw YF，Kao JH，Piratvisuth T，et al.Asian-Pacific consensus statement on the management of chronic hepatitis B：a 2012 update ［J］.Hepatol Int，2012，6 (3)：531-561. 

[10］Lok AS，McMahon BJ.Chronic hepatitis B：update 2009 ［J］.Hepatology，2009，50(3)：661-662. 

[11］Locarnini S.Molecular virology of hepatitis B virus ［J］.Semin Liver Dis，2004，24 Suppl 1：3-10. 

[12］Levrero M，Pollicino T，Petersen J，et al.Control of cccDNA function in hepatitis B virus infection ［J］.J Hepatol，2009，51(3)：581-592. 

[13］Wei Y，Neuveut C，Tiollais P，et al.Molecular biology of the hepatitis B virus and role of the X gene ［J］.Pathol Biol (Paris)，2010，58(4)：267-272. 

[14］Abu-Amara M，Feld JJ.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? ［J］.Semin Liver Dis，2013，33(2)：157-166. 

[15］Wursthorn K，Lutgehetmann M，Dandri M，et al.Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B ［J］.Hepatology，2006，44(3)：675-684. 

[16］Zoulim F.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection ［J］.Antiviral Res，2004，64(1)：1-15. 

[17］Balsano C，Alisi A.Viral hepatitis B：established and emerging therapies ［J］.Curr Med Chem，2008，15(9)：930-939. 

[18］Fung J，Lai CL，Seto WK，et al.Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B ［J］.J Antimicrob Chemother，2011，66(12)：2715-2725. 

[19］Kamiya N.The mechanisms of action of antivials against hepatitis B virus infection ［J］.J Antimicrob Chemother，2003，51(5)：1085-1089. 

[20］Gish R，Jia JD，Locarnini S，et al.Selection of chronic hepatitis B therapy with high barrier to resistance ［J］.Lancet Infect Dis，2012，12(4)：341-353. 

[21］Reijnders JG，Janssen HL.Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs：is the glass half full or half empty ? ［J］.Hepatology，2013，58(6)：1885-1887. 

[22］Chang TT，Liaw YF，Wu SS，et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B ［J］.Hepatology，2010，52(3)：886-893. 

[23］Marinos G，Naoumov NV，Williams R.Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection ［J］.Hepatology，1996，24(5)：991-995. 

[24］Boni C，Bertolatti A，Penna A，et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B ［J］.J Clin Invest，1998，102(5)：968-975. 

[25］Boni C，Penna A，Ogg GS，et al.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B：new perspectives for immune therapy ［J］.Hepatology，2001，33(4)：963-971. 

[26］Evans A，Riva A，Cooksley H，et al.Programmed death 1 expression during antiviral treatment of chronic hepatitis B：impact of hepatitis B e-antigen seroconversion ［J］.Hepatology，2008，48(3)：759-769. 

[27］Zhang JY，Song CH，Shi F，et al.Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment ［J］.PLoS One，2010，5(11)：e13869. 

[28］Yeh CT，Hsu CW，Chen YC，et al.Withdrawal of lamivudine in HBeAg positive chronic hepatitis B patients after achieving effective maintained virological suppression ［J］.J Clin Virol，2009，45(2)：114-118. 

[29］Liaw YF，Leung N，Kao JH，et al.Asian-Pacific consensus statement on the management of chronic hepatitis B：a 2008 update ［J］.Hepatol Int，2008，2(3)：263-283. 

[30］Lee HW，Lee HJ，Hwang JS，et al.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B ［J］.Hepatology，2010，51(2)：415-421. 

[31］Lok AS，McMahon BJ.Chronic hepatitis B：update of recommendations ［J］.Hepatology，2004，39(3)：857-861. 

[32］Liang Y，Jiang J，Su M，et al.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy ［J］.Aliment Pharmacol Ther，2011，34(3)：344-352. 

[33］Pan XF，Zhang K，Yang XA，et al.Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients ［J］.PLoS One，2013，8(7)：e68568. 

[34］Liaw YF，Leung N，Guan R，et al.Asian-Pacific consensus statement on the management of chronic hepatitis B：a 2005 update ［J］.Liver Int，2005，25(3)：472-489. 

[35］Jiang JN，Huang ZL，He LX，et al.Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs ［J］.J Clin Gastroenterol，2014［Epub ahead of print］

[36］Jeng WJ，Sheen IS，Chen YC，et al.Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients ［J］.Hepatology，2013，58(6)：1888-1896. 

[37］Seto WK，Hui AJ，Wong WS，et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B：a multicentre prospective study ［J］.Gut，2014［Epub ahead of print］

[38］Song BC，Suh DJ，Lee HC，et al.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea ［J］.Hepatology，2000，32(4 Pt 1)：803-806. 

[39］Reijnders JG，Perquin MJ，Zhang NP，et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B ［J］.Gastroenterology，2010，139(2)：491-498. 

[40］Fung SK，Wong F，Hussain M，et al.Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B ［J］.J Viral Hepat，2004，11(5)：432-438. 

[41］Chan HL，Wang H，Niu J，et al.Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B：a double-blind，placebo-controlled trial ［J］.Antivir Ther，2007，12(3)：345-353. 

[42］Hadziyannis SJ，Sevastianos V，Rapti I，et al.Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir ［J］.Gastroenterology，2012，143(3)：629-636. 

[43］Liu F，Wang L，Li XY，et al.Poor durability of lamivudine effectiveness despite stringent cessation criteria：a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients ［J］.J Gastroenterol Hepatol，2011，26(3)：456-460. 

[44］Dienstag JL，Goldin RD，Heathcote EJ，et al.Histological outcome during long-term lamivudine therapy ［J］.Gastroenterology，2003，124(1)：105-117. 

[45］Xu B，Lin LY，Xu GG，et al.Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B［J］.J Gastroenter Hepatol，2014.［Epub ahead of print］

[46］Hadziyannis SJ，Tassopoulos NC，Heathcote EJ，et al.Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years ［J］.Gastroenterology，2006，131(6)：1743-1751. 

[47］Marcellin P，Chang TT，Lim SG，et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B ［J］.Hepatology，2008，48(3)：750-758. 

[48］Liaw YF.Reversal of cirrhosis：an achievable goal of hepatitis B antiviral therapy ［J］.J Hepatol，2013，59(4)：880-881. 

[49］Schiff ER，Lee SS，Chao YC，et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.Clin Gastroenterol Hepatol，2011，9(3)：274-276. 

[50］Liaw YF，Raptopoulou-Gigi M，Cheinquer H，et al.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompesation：a randomized，open-label study ［J］.Hepatology，2011，54(1)：91-100. 

[51］Liaw YF，Sheen IS，Lee CM，et al.Tenofovir disoproxil fumarate (TDF)，emtricitabine/TDF，and entecavir in patients with decompesated chronic hepatitis B liver disease ［J］.Hepatology，2011，53(1)：62-72. 

[52］Yuen MF，Seto WK，Chow DH，et al.Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease ［J］.Antivir Ther，2007，12(8)：1295-1303. 

[53］Liaw YF，Sung JJ，Chow WC，et al.The CALM Study Group.Lamivudine for patients with chronic hepatitis B and advanced liver disease ［J］.N Engl J Med，2004，351(15)：1521-1531. 

[54］Matsumoto A，Tanaka E，Rokuhara A，et al.The Inuyama Hepatitis Study Group.Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B：a multicenter retrospective study of 2795 patients ［J］.Hepatol Res，2005，32(3)：173-184. 

[55］Di Marco V，Marzano A，Lampertico P，et al.Italian Association for the Study of the Liver (AISF) Lamivudine Study Group，Italy.Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine ［J］.Hepatology，2004，40(4)：883-891. 

[56］Sung JJ，Tsoi KK，Wong VW，et al.Meta-analysis：treatment of hepatitis B infection reduces risk of hepatocellular carcinoma ［J］.Aliment Pharmacol Ther，2008，28(9)：1067-1077. 

[57］Papatheodoridis GV，Lampertico P，Manolakopoulos S，et al.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy：a systematic review ［J］.J Hepatol，2010，53(2)：348-356. 

[58］Eun JR，Lee HJ，Kim TN，et al.Risk assessment for the development of hepatocellular carcinoma：according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease ［J］.J Hepatol，2010，53(1)：118-125. 

[59］Su TH，Hu TH，Lin CC，et al.Reduction of hepatocellular carcinoma in hepatitis B related cirrhosis patients with long-term entecavir therapy-an interim report of C-TEAM study ［J］.Hepatology，2013，58 Suppl 1：301A. 

[60］Wu CY，Lin JT，Ho HJ，et al.Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study ［J］.Gastroenterology，2014，147(1)：143-151. 

[61］Kumada T，Toyoda H，Tada T，et al.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients：a propensity score analysis ［J］.J Hepatology，2013，58(3)：427-433. 

[62］Papatheodoridis GV，Manolakopoulos S，Touloumi G，et al.Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy：results of the nationwide HEPNET.Greece cohort study ［J］.Gut，2011，60(8)：1109-1116. 

[63］Fattovich G，Bortolotti F，Donato F.Natural history of chronic hepatitis B：special emphasis on disease progression and prognostic factors ［J］.J Hepatology，2008，48(2)：335-352. 

[64］Papatheodoridis G，Manolakopoulos S，Touloumi G，et al.Hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-) with or without cirrhosis treated with entecavir：results of the nationwide HepNet Greece Cohort Study ［J］.J Hepatol，2013，58 Suppl 1：S312. 

[65］Lampertico P，Soffredini R，Yurdaydin C，et al.Four years of tenofovir monotherapy for NUC na?ve field practice European patients suppress HBV replication in most patients with a favourable renal safety profile but do not prevent HCC in patients with or without cirrhosis ［J］.Hepatology，2013，58 Suppl 1：653A. 

[66］Papatheodoridis GV，Dalekos GN，Yurdaydin C，et al.Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF) ［J］.Hepatology，2013，58 Suppl 1：302A. 

[67］Cho JY，Paik YH，Sohn W，et al.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease ［J］.Gut，2014.［Epub ahead of print］

[68］Lampertico P，Soffredini R，Vigano M，et al.5-year entecavir treatment in NUC-na?ve，field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhosis ［J］.J Hepatol，2013，58 Suppl 1：S306. 

[69］Hosaka T，Suzuki F，Kobayashi M，et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection ［J］.Hepatology，2013，58(1)：98-107. 

[70］Wong GL，Chan HL，Chan HY，et al.Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment ［J］.Gastroenterology，2013，144(5)：933-944. 

[71］Kim WR，BergT，Loomb R，et al.Long-term tenofovir disoproxil fumarate therapy and the risk of hepatocellular carcinoma ［J］.J Hepatol，2013，58 Suppl 1：S19. 

[72］Hilleret MN，Larrat S，Stanke-Labesque F，et al.Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough? ［J］.J Hepatol，2011，55(6)：1468-1469. 

[73］Berg T，Marcellin P，Zoulim F，et al.Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic hepatitis B virus infection ［J］.Gastroenterology，2010，139(4)：1207-1217. 

[74］World Health Organization.Adherence to long-term therapies：evidence for action［EB/OL］.

[2014-08-12］.http：//www.who.int/chp/knowledge/publications/adherencefull_report.pdf. 

[75］Chotiyaputta W，Peterson C，Ditah FA，et al.Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B ［J］.J Hepatol，2011，54(1)：12-18. 

[76］Lee M，Keeffe EB.Study of adherence comes to the treatment of chronic hepatitis B ［J］.J Hepatol，2011，54(1)：6-8. 

[77］Giang L，Sellinger CP，Lee AU.Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires ［J］.World J Hepatol，2012，4(2)：43-49. 

[78］Sun MS，Wang GQ，Zhang W，et al.The current status of lamivudine-treated patients with chronic hepatitis B ［J］.Zhongguo Yufang Yixue Zazhi，2012，13(1)：18-22(in Chinese). 孙秘书，王贵强，张伟，等.拉米夫定经治慢性乙型肝炎患者治疗现状调查分析 ［J］.中国预防医学杂志，2012，13(1)：18-22. 

[79］Ye LH，Hu ZQ，Li ZL.A study on compliance of chronic hepatits B patients with treatment ［J］.Shiyong Ganzangbing Zazhi，2013，16(2)：155-156(in Chinese). 叶丽华，胡兆琴，李正莲.慢性乙型肝炎患者诊断治疗依从性行为调查 ［J］.实用肝脏病杂志，2013，16(2)：155-156. 

[80］An P，Bian L，Yin B，et al.Risk factors of gene-resistant mutations in different nucleosides ［J］.Hepato-Gastroenterology，2012，59 (113)：228-230. 

[81］Zeng MD，Mao YM，Yao GB，et al.Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B ［J］.Liv Int，2012，32(1)：137-146. 

[82］Sun J，Xie Q，Tan DM，et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients：a randomized，controlled study ［J］.Hepatology，2014，59(4)：1283-1292. 

[83］Experts attending the discussion on hepatitis B virus drug resistance.Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management ［J］.Zhongguo Bingdubing Zazhi，2013，3(1)：1-11(in Chinese). 参加乙型肝炎耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理［J］.中国病毒病杂志，2013，3(1)：1-11. 

[84］Pipili C，Cholongitas E，Papatheodoridis G.Review article：nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease ［J］.Aliment Pharmacol Ther，2014，39(1)：35-46. 

[85］Jung YK，Yeon JE，Choi JH，et al.Fanconi’s syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient ［J］.Gut Liver，2010，4(3)：389-393. 

[86］Verhelst D，Monge M，Meynard JL，et al.Fanconi syndrome and renal failure induced by tenofovir：a first case report ［J］.Am J Kidney Dis，2002，40(6)：1331-1333. 

[87］Gaspar G，Monereo A，García-Reyne A，et al.Fanconi syndrome and acute renal failure in a patient treated with tenofovir：a call for caution ［J］.AIDS，2004，18(2)：351-352. 

[88］Pol1 S，Lampertico P.First-line treatment of chronic hepatitis B with entecavir or tenofovir in real-life settings：from clinical trials to clinical practice ［J］.J Viral Hepat，2012，19(6)：377-386.

[89］Liaw YF，Gane E，Leung N，et al.2-Year GLOBE trial results：telbivudine is superior to lamivudine in patients with chronic hepatitis B［J］.Gastroenterology，2009，136(2)：486-495. 

[90］Lai CL，Gane E，Liaw YF，et al.Telbivudine versus lamivudine in patients with chronic hepatitis B ［J］.N Engl J Med，2007，357(25)：2576-2588. 

[91］Ren JB，Wang Y，Li HY，et al.Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients ［J］.Zhonghua Ganzangbing Zazhi，2012，20(9)：641-643(in Chinese)任江波，王宇，李红艺，等.替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析 ［J］.中华肝脏病杂志，2012，20(9)：641-643. 

[92］Chan HL，Wong VW，Tse AM，et al.Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response ［J］.Clin Gastroenterol Hepatol，2007，5(12)：1462-1468. 

[93］Ning Q，Han M，Sun Y，et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B：a randomised open-label trial (OSST trial) ［J］.J Hepatol，2014［Epub ahead of print］

[94］Xie Q，Zhou HJ，Bai XF，et al.A Randomized，open-label clinical study of combined peginterferon alfa-2a (40KD) and entecavir treatment for HBeAg-positive chronic hepatitis B［J］.Clin Infect Dis，2014［Epub ahead of print］